Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cyclobenzaprine Hydrochloride

FDA-approved product (tablet, oral), marketed as Amrix, Cyclobenzaprine Hydrochloride, Flexeril and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Cyclobenzaprine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cerebral palsy
  • Muscle spasm
  • Myalgia
  • Spasticity
  • Spinal cord disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other centrally acting agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA11.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli18.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cyclobenzaprine Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cyclobenzaprine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Bioequivalence Study of Cyclobenzaprine Hydrochloride 10 mg Tablets, USP Under Fasting Conditions

    NCT00778037 · start 2006-09

    Registered record
    Registry ID
    NCT00778037
    Conditions
    Healthy
    Interventions
    Cyclobenzaprine hydrochloride 10 mg tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-09
    Completion
    2006-11
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCyclobenzaprine hydrochloride 10 mg tablet
    PhaseNot applicable
    Registry statusCompleted

  • Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine

    NCT00635037 · start 2004-06

    Registered record
    Registry ID
    NCT00635037
    Conditions
    Myofascial Pain Syndromes
    Interventions
    bupivacaine and acupuncture
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-06
    Completion
    2006-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyofascial Pain Syndromes
    Interventionbupivacaine and acupuncture
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial

    NCT00790270 · start 2003-01

    Registered record
    Registry ID
    NCT00790270
    Conditions
    Cervical Strain
    Interventions
    Cyclobenzaprine; Ibuprofen; Ibuprofen plus Cyclobenzaprine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-01
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCervical Strain
    InterventionCyclobenzaprine; Ibuprofen; Ibuprofen plus Cyclobenzaprine
    PhasePhase 2
    Registry statusCompleted

  • To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets

    NCT00913419 · start 1988-11

    Registered record
    Registry ID
    NCT00913419
    Conditions
    Depression
    Interventions
    Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories; Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1988-11
    Completion
    1988-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    InterventionCyclobenzaprine HCl Tablets 10 mg, Cord Laboratories; Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
    PhasePhase 1
    Registry statusCompleted

  • An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm

    NCT00246389

    Registered record
    Registry ID
    NCT00246389
    Conditions
    Pain; Spasm
    Interventions
    cyclobenzaprine hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2004-07
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Spasm
    Interventioncyclobenzaprine hydrochloride
    PhasePhase 4
    Registry statusCompleted